GLP-1 Receptor Agonists Slow Epigenetic Aging, a Measure of the Harms Done by Excess Visceral Fat

Weight loss drugs are a major focus of the pharmaceutical industry at present. It remains to be seen as to what will emerge as the next big class of weight loss drugs following GLP-1 receptor agonists. Since the primary effect of GLP-1 receptor agonist drugs is a reduction in calorie intake, all of the gathered data in humans is really just a sizable confirmation of the harms done by the presence of excess visceral fat tissue, and the benefits gained from losing that fat via dieting. It wouldn’t much matter how these patients achieved that outcome, the resulting benefits would look much the same – and have in the past as a result of other strategies for weight loss.

Researchers analyzed data from a previously published clinical trial of 108 adults with HIV-associated lipohypertrophy, a condition in which excess fat builds up around the abdomen. About half of the participants received weekly injections of semaglutide, with the rest receiving placebo injections. The team used a set of biological “epigenetic clocks” to track cellular aging over the 32-week treatment period. These clocks detect DNA methylation, chemical marks on DNA that help regulate how genes are turned on or off without changing the genetic sequence itself. By measuring changes in these marks, the team could assess whether the treatment was associated with a slower or faster biological aging pattern.

Participants treated with semaglutide exhibited a broad pattern of slower biological aging across epigenetic clocks linked to inflammation and blood, brain, heart, kidney, liver and metabolic health. The drug slowed the pace of biological aging by 9%, as measured by the DunedinPACE epigenetic clock. The drug significantly slowed biological processes associated with the risk of all-cause mortality and age-related disease, as measured by the PCGrimAge epigenetic clock. Research suggests there are several mechanisms by which semaglutide may influence biological aging. By reducing inflammation and metabolic stress, GLP-1 drugs decreased chronic immune activation, a primary driver of accelerated aging in people with HIV. They also reduce visceral and ectopic fat that accumulates around the abdomen and organs, which may help curb the inflammatory and metabolic signals that promote aging.